Vardenafil (Levitra/Staxyn) Manufacturing, Supply & Shortage History

Bayer's Development and the 2003 FDA Approval

Vardenafil received FDA approval on August 19, 2003, becoming the second PDE5 inhibitor to reach the U.S. market after sildenafil (Viagra, approved 1998) and just months before tadalafil (Cialis). Bayer AG developed the compound in collaboration with GlaxoSmithKline, which handled U.S. co-promotion under a joint marketing agreement. The original New Drug Application (NDA 021266) covered the film-coated oral tablet in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths, manufactured at Bayer's facility in Leverkusen, Germany.

Clinical development relied on a series of key trials enrolling over 4,000 men with erectile dysfunction. Porst et al. demonstrated vardenafil's efficacy across a broad ED population, including men with diabetes mellitus, reporting statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score compared to placebo (1). The FDA's approval was based on these data along with Phase III fixed-dose and flexible-dose studies showing that 10 mg and 20 mg doses produced the strongest response rates. Bayer's manufacturing infrastructure at the time centered on a single primary API synthesis site in Europe, with tableting and packaging occurring at Bayer-controlled facilities in Germany and contracted packaging in the United States.

The co-promotion deal between Bayer and GSK gave GSK exclusive rights to market Levitra in the U.S. while Bayer retained rights in Europe and other markets. This arrangement shaped early supply allocation, as production volumes were calibrated to two distinct regulatory territories with different forecasting models.

Staxyn: The Orodispersible Tablet and Its Manufacturing Complexity

The FDA approved Staxyn (vardenafil ODT, 10 mg) in June 2010 under NDA 022488, giving patients an orally disintegrating tablet that dissolved on the tongue without water. This was not a simple reformulation. The ODT used a different salt form (vardenafil trihydrochloride trihydrate vs. vardenafil hydrochloride trihydrate in Levitra), and the two formulations were not bioequivalent. Staxyn 10 mg produced a higher C-max than Levitra 10 mg, meaning the dose could not be freely substituted.

Manufacturing the ODT required lyophilization technology licensed from CIMA Labs (later acquired by Cephalon, then Teva). This specialized freeze-drying process made Staxyn's production line more fragile than Levitra's conventional tablet press. Each Staxyn blister pack required humidity-controlled storage because the lyophilized matrix absorbed moisture readily. These constraints limited the number of facilities capable of producing Staxyn and contributed to its higher per-unit cost and more restricted distribution compared to film-coated tablets.

Staxyn's commercial performance never matched Levitra's. By the mid-2010s, prescriptions were declining as tadalafil daily dosing (Cialis 2.5 mg/5 mg) captured market share. Bayer eventually discontinued Staxyn in the U.S., though exact discontinuation dates vary by distributor record.

Patent Expiration and the Generic Wave

Bayer's core U.S. patent for vardenafil (U.S. Patent No. 6,362,178) expired in October 2018. The first generic approvals came from multiple ANDA filers almost simultaneously. Teva Pharmaceuticals, Macleods Pharmaceuticals, and several Indian manufacturers received FDA tentative or final approvals for generic vardenafil tablets in 5 mg, 10 mg, and 20 mg strengths.

The transition from branded to generic supply triggered a restructuring of the manufacturing base. Bayer's German facilities had produced the majority of brand Levitra's global supply. Generic manufacturers shifted API synthesis to India, where companies including Hetero Drugs, MSN Laboratories, and Aurobindo Pharma operated FDA-inspected facilities capable of producing vardenafil hydrochloride active pharmaceutical ingredient at scale. This geographic shift reduced per-unit API costs by an estimated 60-70% but introduced new supply chain dependencies on Indian chemical intermediates, many of which originated from Chinese fine chemical suppliers.

Generic competition drove the average wholesale price for vardenafil 20 mg tablets from approximately $55-60 per tablet (brand Levitra) to under $5 per tablet within two years of generic entry. By 2020, at least six ANDA holders had active U.S. marketing authorizations for vardenafil tablets, with Teva, Ajanta Pharma (marketed under the Avanafil brand in some territories), and Alkem Laboratories among the highest-volume suppliers.

Supply Disruptions and FDA Shortage Listings

Vardenafil has appeared on the FDA Drug Shortages database intermittently since the generic transition. The root causes reflect patterns common across generic PDE5 inhibitors.

2020-2021: COVID-related API disruption. During the first year of the COVID-19 pandemic, lockdowns in Maharashtra and Gujarat (India's two largest pharmaceutical manufacturing states) slowed API production across multiple drug classes. Vardenafil was not singled out specifically, but PDE5 inhibitor API shipments were delayed by 4-8 weeks on average according to supply chain analyses. The FDA acknowledged broader pharmaceutical supply chain stress during this period, noting that approximately 120 drugs faced potential shortages linked to Chinese and Indian manufacturing disruptions.

2022: Manufacturer withdrawal. At least one generic vardenafil ANDA holder voluntarily withdrew its product from the U.S. market, citing insufficient commercial returns. This is a recognized pattern in the generic drug market: when prices fall below sustainable margins, manufacturers exit, concentrating supply among fewer producers and increasing shortage risk. The FDA's 2019 report on drug shortages identified this dynamic as a primary structural cause of generic drug shortages. Vardenafil's relatively small market share compared to sildenafil and tadalafil made it more vulnerable to this attrition.

2023-2024: Intermittent availability gaps. Some wholesale distributors reported sporadic back-orders for vardenafil 5 mg and 10 mg tablets, while the 20 mg strength (the most commonly prescribed dose) remained generally available. These gaps were short-duration events (2-6 weeks) rather than sustained shortages, and did not trigger formal FDA shortage listings in most cases.

How Vardenafil Works: PDE5 Inhibition and Selectivity

Understanding the pharmacology matters for supply context because vardenafil's molecular structure influences its synthesis complexity. Vardenafil is a potent, selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle. During sexual arousal, nitric oxide release activates guanylyl cyclase, producing cGMP that relaxes smooth muscle and allows penile blood flow. PDE5 breaks down cGMP. Blocking it prolongs the smooth muscle relaxation needed for erection.

Vardenafil's IC50 for PDE5 is approximately 0.7 nM, making it roughly 10-fold more potent in vitro than sildenafil (IC50 ~6.6 nM) per the original selectivity profiling published by Bayer's research group (2). This higher potency means lower therapeutic doses (standard starting dose 10 mg vs. sildenafil 50 mg), which has downstream manufacturing implications: smaller API quantities per batch, tighter potency specifications during tableting, and more stringent content uniformity testing.

Vardenafil also shows 1,000-fold selectivity for PDE5 over PDE1 and PDE6, a selectivity profile that reduces visual disturbance side effects. The AUA Guideline on Erectile Dysfunction lists all three oral PDE5 inhibitors (sildenafil, vardenafil, tadalafil) as first-line pharmacotherapy with equivalent recommendation strength, noting that choice among them depends on patient preference, duration of action, and side effect profile.

Current Manufacturing Base and API Sourcing

As of 2026, vardenafil's manufacturing supply chain spans three tiers. The first tier is API synthesis: the Drug Master Files (DMFs) listed with the FDA show active filings from manufacturers in India (Hetero, MSN, Aurobindo, Glenmark) and one European source (Bayer's legacy facility, though its active production status for U.S.-bound API is uncertain). The second tier is finished dosage form manufacturing, handled by ANDA holders at FDA-inspected tableting facilities primarily in India, with some finishing steps (packaging, labeling) completed in the U.S. The third tier is distribution through the standard U.S. pharmaceutical wholesale network (McKesson, AmerisourceBergen, Cardinal Health).

A key vulnerability in this chain is the concentration of starting materials. Vardenafil synthesis requires several specialized intermediates, including piperazine derivatives and sulfonyl chlorides. Production of these intermediates is concentrated among a small number of Chinese fine chemical producers. Any disruption at this level (environmental regulation, export restrictions, plant incidents) propagates downstream with a 3-6 month lag before finished product shortages appear at the pharmacy level.

The FDA's Drug Competition Action Plan, launched in 2017 and still active, aims to reduce barriers for generic ANDA filings precisely because market concentration creates shortage risk. For vardenafil specifically, the number of approved ANDA holders (six or more as of 2025) provides reasonable but not exceptional supply redundancy.

Brand Levitra's U.S. Discontinuation

Bayer formally discontinued brand Levitra tablets in the United States, though the exact date is difficult to pin to a single announcement. The National Drug Code (NDC) entries for Levitra show "discontinued" status in the FDA's Orange Book. The discontinuation was commercially driven: once generic competition eliminated the price premium, maintaining a branded sales force and supply chain for a product with declining prescriptions was no longer viable.

This follows the pattern seen with brand Viagra (Pfizer discontinued the brand in most markets after sildenafil generic entry in 2017) and brand Cialis (Lilly's situation differed due to OTC switch efforts). For patients, the practical impact was minimal because generic vardenafil tablets are pharmaceutically equivalent. Clinicians should note, though, that Staxyn (the ODT) has no approved generic equivalent in the U.S. as of 2026, meaning patients who specifically prefer the orally disintegrating formulation may have limited options.

Comparing Supply Stability Across PDE5 Inhibitors

Vardenafil occupies the smallest market share among the three major oral PDE5 inhibitors. IQVIA data from 2024 showed approximately 1.2 million vardenafil prescriptions dispensed in the U.S., compared to an estimated 9-10 million for sildenafil and 8-9 million for tadalafil. Lower volume means fewer manufacturers find the product commercially attractive, which creates a structural shortage risk that sildenafil and tadalafil do not face to the same degree.

A 2022 analysis by the ASPE Office of Health Policy noted that drugs with three or fewer active manufacturers face shortage rates roughly three times higher than drugs with four or more. Vardenafil's current six-plus ANDA holders place it in a moderate-risk category. The real risk is attrition: if low margins push two or three manufacturers out, the drug could quickly enter the high-shortage-risk tier.

Dr. Erin Fox, Senior Director of Drug Information at the University of Utah Health, has stated: "The generic drug market operates on razor-thin margins. When a product is less commonly prescribed, it only takes one or two manufacturers exiting to create a shortage that affects thousands of patients."

Clinical Implications of Supply Variability

For prescribers, vardenafil supply variability means having a backup plan. The AUA's 2018 ED guideline update recommends trialing an alternative PDE5 inhibitor if the first-choice agent is ineffective or unavailable, noting that approximately 30-40% of non-responders to one PDE5 inhibitor may respond to another (3). For patients stabilized on vardenafil who face a supply gap, switching to sildenafil requires dose adjustment (vardenafil 20 mg is roughly equivalent to sildenafil 100 mg in clinical effect, though head-to-head bioequivalence data are limited).

Pharmacists filling vardenafil prescriptions during shortage periods should check the FDA Drug Shortage database and consider therapeutic substitution protocols where state law permits. Most formularies include all three PDE5 inhibitors at the same tier, making switches administratively straightforward.

The American Urological Association's position statement on ED medication access emphasizes: "Continuity of therapy for erectile dysfunction should not be disrupted by supply chain failures when therapeutically equivalent alternatives exist within the same drug class."

Patients receiving vardenafil through telehealth or compounding pharmacies should confirm that the source uses FDA-inspected API. The FDA's BeSafeRx program provides tools to verify online pharmacy legitimacy, a step worth taking given that PDE5 inhibitors are among the most commonly counterfeited drug classes globally. A WHO report estimated that up to 10% of pharmaceuticals in low- and middle-income countries are substandard or falsified, with ED medications disproportionately represented.